Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs Wellorithm

Two GLP-1 desks, one scoreboard. We put Sesame Care and Wellorithm head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 39 · Grade C

Wellorithm

Visit Wellorithm Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 58 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make Wellorithm a bad call — it's best for readers who specifically want an oral dissolving tablet and will complete an intake before learning any cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
40
Supply Reliability
92
70
Transparency
94
28
Access Breadth
84
84
Clinical Oversight
80
40
Track Record
92
58
Sesame CareBrief Score 87 · 58Wellorithm

Price, coverage & the tracker

Sesame CareWellorithm
Brief Score87/100 (B+)58/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)Pricing not published
TirzepatideBrand Zepbound (price varies)Pricing not published
CoverageNationwide marketplace49 states (not Louisiana)
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Wellorithm: Nothing to track — no price appears anywhere on the public site, and the pricing page 404s.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.